Jianliang Yang

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peping, Beijing, China

Are you Jianliang Yang?

Claim your profile

Publications (18)29.94 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: The role of rituximab in combination with CHOP regimen in patients with stage I diffuse large B-cell lymphoma (DLBCL) remains to be defined. We aimed to compare CHOP plus rituximab (R-CHOP) with CHOP alone and determine the value of radiotherapy in these patients. Methods: Between 2003 and 2009, 140 untreated patients with stage I DLBCL were retrospectively analyzed in this study. Results: Seventy-eight patients were treated in R-CHOP group and 62 in CHOP group. Ninety-one patients received additional radiotherapy at the end of chemotherapy. The different treatment groups were well-balanced with respect to baseline characteristics. Complete response (CR) rate was 77% both in R-CHOP and CHOP groups (P=0.945). After a median follow-up period of 56 months, patients received R-CHOP regimen had similar 5-year progression-free survival (PFS) (76% vs. 85%; log-rank P=0.215) and 5-year overall survival (OS) (90% vs. 96%; log-rank P=0.175) compared with those with CHOP alone. Patients with radiotherapy had significantly increased 5-year PFS compared with those who had chemotherapy alone (86% vs. 71%; log-rank P=0.005). At multivariate analysis, patients who had CR (P=0.008) and received radiotherapy (P=0.003) were significantly associated with superior PFS. Conclusions: CHOP alone could be as effective as R-CHOP regimen and additional radiotherapy would be necessary for stage I or stage I non-bulky DLBCL patients.
    Chinese Journal of Cancer Research 11/2015; 27(5):516-23. DOI:10.3978/j.issn.1000-9604.2015.10.04 · 1.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is an efficient treatment of non-Hodgkin's lymphoma (NHL). This study aimed to assess the efficacy and toxicity of dose-adjusted CHOP alone or in combination with rituximab (R-CHOP) by examining the stem cell mobilization in NHL patients. Factors affecting the collection of CD34(+) cells were also explored. Methods: Our retrospective study included 39 patients eligible for autologous stem cell transplantation: 14 patients who expressed CD20 and were financially eligible received R-CHOP for autologous peripheral blood stem cell (APBSC) mobilization; the remaining 25 patients received CHOP. Results: The median CD34(+) cell yield was 7.01 × 10(6) cells/kg body weight (range 1.49-28.39 × 10(6) cells/kg body weight), with only two patients failing to meet the target CD34(+) cell harvest of ≥2.0 × 10(6) cells/kg body weight. The median number of apheresis procedures per patient was 1 (range 1-3). The APBSC mobilization yield of the CHOP group appeared to be higher than that of the R-CHOP group (P = 0.005), whereas the success rate was similar between groups. R-CHOP elevated the complete response (CR) rate in B cell lymphoma patients as compared with CHOP (P = 0.01). No significant differences in toxicity or engraftment were observed between the two groups. Conclusion: The present study demonstrated that dose-adjusted CHOP chemotherapy effectively mobilized APBSCs in NHL patients and that the addition of rituximab to dose-adjusted CHOP chemotherapy elevated the CR rate for patients with B-cell lymphoma.
    Ai zheng = Aizheng = Chinese journal of cancer 09/2015; 34(3):52. DOI:10.1186/s40880-015-0045-3 · 2.16 Impact Factor
  • Yihebali Chi · Jianliang Yang · Sheng Yang · Yongkun Sun · Bo Jia · Yuankai Shi ·
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and efficacy of sorafenib in combination with FOLFOX4 (oxaliplatin/leucovorin (LV)/5-fluorouracil) as first-line treatment for advanced gastric cancer, we performed a phase I dose-finding study in nine evaluable patients with unresectable locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma. According to modified Fibonacci method, the design of this study was to guide elevation of the sorafenib dosage to the next level (from 200 mg twice daily to 400 mg twice daily and then, if tolerated, 600 mg twice daily). If the patient achieved complete response (CR), partial response (PR) or stable disease (SD) after eight cycles of treatment, combination chemotherapy was scheduled to be discontinued and sorafenib monotherapy continued at the original dose until either disease progression or unacceptable toxicity. In sorafenib 200 mg twice daily group, DLT was observed in 1 of 6 patients, and in 400 mg twice daily group, it was observed in 2 of 3 patients. Seven of 9 (77.8%) evaluable patients achieved PR, with a median overall survival (OS) of 11.8 [95% confidence interval (CI): 8.9-14.7] months. Common adverse effects include hand-foot syndrome, leukopenia, neutropenia, anorexia, and nausea. Twice-daily dosing of sorafenib 200 mg in combination with FOLFOX4 was proven effective and safe for the treatment of advanced gastric cancer, and could be an appropriate dosage for subsequent phase II clinical studies.
    Chinese Journal of Cancer Research 06/2015; 27(3):239-46. DOI:10.3978/j.issn.1000-9604.2015.06.08 · 1.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the clinicopathological features and outcomes of lymphoma in pregnancy. A total of 21 patients with lymphoma in pregnancy were diagnosed and treated at our hospital between January 1999 and January 2012. The clinicopathological data were analyzed retrospectively. There were 11 cases of Hodgkin's lymphoma (HL) and 10 cases of nodular sclerosis classical Hodgkin's lymphoma (NSCHL). And, among 10 cases of non-Hodgkin's lymphomas (NHL), there were diffuse large B cell lymphoma (n = 6),B-cell lymphoma, non-classifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (n = 1), small lymphocytic lymphoma (n = 1), anaplastic large cell lymphoma with anaplastic lymphoma kinase (ALK) positive (n = 1) and T-cell lymphoblastic lymphoma (n = 1). The median age was 26(22-35) years.Superficial lymphadenopathy was more common in HL than in NHL (10/11 vs 3/10, P = 0.008). At diagnosis, bulky disease and extranodal involvement were more prevalent in NHL than in HL (8/10 vs 2/11, P = 0.009; 7/10 vs 2/11, P = 0.030). All patients received chemotherapy and those with early stages also had combined radiotherapy. Ten patients with HL and 6 patients with NHL achieved complete remission. During a median follow-up of 90 months for HL, the 5-year progression-free survival (PFS) and overall survival (OS) rates were 87.5% and 100% respectively. And during a median follow-up of 31 months for NHL, the 2-year PFS and OS rates were 66.7% and 77.8% respectively. The values of PFS and OS of NHL were inferior to those of HL (P = 0.073 and P = 0.066 respectively).One case of HL and 1 case of NHL received chemotherapy in the second trimester. The patients and their children experienced good outcomes. NSCHL is the most prevalent subtype of HL during pregnancy. B cell lymphoma and aggressive subtypes are most common for NHL during pregnancy. The outcomes of NHL are inferior to those of HL during pregnancy.
    Zhonghua yi xue za zhi 02/2015; 95(6):425-429. DOI:10.3760/cma.j.issn.0376-2491.2015.06.007
  • [Show abstract] [Hide abstract]
    ABSTRACT: The study evaluated the effectiveness of autologous hematopoietic stem cell transplantation (AHSCT) in the treatment of lymphoblastic lymphoma (LL). We retrospectively analyzed the data from 41 patients with chemotherapy-sensitive LL who underwent hematopoietic stem cell transplantation (HSCT) from December 1989 to December 2009 in a single institution. HSCT was conducted as first-line consolidation therapy and salvage therapy in 36 and 5 patients, respectively. The median follow-up was 97.1 months (range, 24.6-173.1 months). The 5-year overall survival (OS) and event-free survival (EFS) rate were 64% and 47% for the initially treated patients, respectively, and were both 20% for the relapsed ones. Bone marrow (BM) involvement and chemotherapy cycles prior to transplantation were identified as significant prognostic factors for EFS in multivariate analysis. These results confirm that AHSCT is a reasonable option for chemotherapy-sensitive LL patients in first complete remission (CR1).
    Chinese Journal of Cancer Research 02/2015; 27(1):66-73. DOI:10.3978/j.issn.1000-9604.2015.02.04 · 1.94 Impact Factor

  • Leukemia and Lymphoma 01/2015; 56(7):1-12. DOI:10.3109/10428194.2014.999323 · 2.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To analyze the clinical features, therapeutic outcome and prognostic factors of mantle cell lymphoma (MCL). Clinical data of a total of 68 patients with MCL admitted from August 2003 to June 2013 in our department were retrospectively analyzed. Of all the patients, the median age was 58.5 years, with marked male predominance (2.8:1), 59 patients (86.8%) were in Ann Arbor stage III/IV. 56 cases (82.4%) primarily showed lymph node involvement, 49 cased showed extranodal involvement and 19 cases (38.8%) had bone marrow involvement. Patients were followed up for 4 to 122 months with a median follow up time of 35 months. The 3- and 5-year overall survival (OS) rates were 78.5% and 64.1%, respectively. The 2- and 3-year progression-free survival (PFS) rates were 41.3% and 23.7%, respectively, and the median time to progression was 20.0 months. The overall response rate (ORR) of CHOP regimen was superior to that of intense regimens (P = 0.036). Univariate analysis showed that stage III/IV,IPI score of 3-5, expression of Ki-67 higher than 30%, elevated LDH, elevated β2-MG, blastic variant, more than 5 lymph nodes involved, and failure to chemotherapy were the negative factors. Multivariate analysis showed that Ki-67 index, LDH and the response to chemotherapy were independent factors affecting survival. Most patients with MCL were elderly males with advanced stage and usually had bone marrow involvement. Although ORR of CHOP regimen is superior to intense regimens, the prognosis of MCL remains poor.
    Zhonghua zhong liu za zhi [Chinese journal of oncology] 12/2014; 36(12):928-32.
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to evaluate the value of different follow-up methods for the detection of first recurrence in lymphoma patients in first complete remission (CR), and to find reasonable long-term follow-up strategies. We retrospectively analyzed 277 lymphoma patients who achieved CR after first-line therapies and subsequently relapsed. All patients were divided into routine surveillance imaging group (group A) and irregular imaging follow-up visit group (group B). To compare the two groups of patients with tumor burden (tumor diameter and number of tumor invasion areas) at the time of relapse, and the number of imaging scans before the relapse. To analyze the main ways of finding lymphoma relapse in the two groups. Among a total of 277 patients, there were 187 patients in the group A and 90 patients in the group B. The tumor recurrence occurred in 120 cases (43.3%) within the first year, and 76 patients (27.4%) in the second year. At the time of diagnosis of recurrence, the average maximum diameter of tumors in the groups A and B were (3.2 ± 2.2) cm and (3.8 ± 2.9) cm, respectively (P = 0.123). The two groups showed slight difference in number of tumor invasion areas (P = 0.050). At the time of diagnosis of recurrence, there were 3 of 121 patients (2.5%) with maximum diameter of tumors more than 8 cm in the group A and 6 of 49 cases (12.2%) in the group B (P = 0.018). In the group A, the patients had in average 4.9 times of imaging scans before recurrence, significantly more than the 0.22 times in the group B (P < 0.001). Among all patients, the diagnosis of recurrence was based on imaging scans only in 59 patients (21.3%). Most lymphoma patients do not benefit from routine surveillance imaging to detect the tumor recurrence. It indicates that we should not rely solely on imaging examinations at follow-up visits, and should pay more attention on clinical signs and symptoms.
    Zhonghua zhong liu za zhi [Chinese journal of oncology] 12/2014; 36(12):933-8.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study, serum free and total light chains (sFLC/sTLC) were measured in 108 serum samples of therapy-naïve patients with DLBCL. Clinicopathologic data and survival outcomes were analyzed according to the results of sFLC/sTLC measurements. Moreover, the association of sFLC/sTLC with absolute monocyte count (AMC) and absolute lymphocyte count (ALC) was evaluated. Elevated sFLC and abnormal κ/λ ratio was present in 42.6% (51/108) and 4.6% (5/108) of patients, respectively. sTLC was successfully measured in 107 serum samples, abnormal sTLC and abnormal κ/λ ratio was found in 28.0% (30/107) and 26.2% (28/107) of patients, respectively. Patients with elevated sFLC more frequently displayed adverse clinical characteristics, including age (P = 0.001), B symptoms (P = 0.022), low ALC (P = 0.024) and hyperglobulinemia (P = 0.012). Patients with elevated sFLC had an inferior overall survival (OS) (P = 0.012) and tended to have shorter progression-free survival (PFS) (P = 0.061) compared to patients with normal sFLC. Abnormal sTLC or abnormal sTLC ratio showed no significant association with clinical outcomes, with exception of abnormal concurrent κ and λ. Only association of sFLC and ALC with survival remained significant after adjusting for the International Prognostic Index (IPI). The measurement of sFLC and ALC at diagnosis might be useful for the prognostic stratification of patients and sTLC measurement was of little prognostic utility in DLBCL.
    Leukemia Research 09/2014; 38(11). DOI:10.1016/j.leukres.2014.09.006 · 2.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To assess the clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphoma (DLBCL). Methods: A retrospective study of 37 patients with primary testicular DLBCL was carried out from November 2003 to May 2012. Their clinical features, survival and prognostic factors were analyzed. Results: During a median follow-up period of 39.8 months (5.4-93.0 months), the median progression-free survival (PFS) was 26.2 months (95% CI: 0-65 months) and the 3-year overall survival (OS) rate was 78.4%. Within the whole cohort, the factors significantly associated with a superior PFS were limited stage (stage I/II), lactate dehydrogenase (LDH) ≤245 U/L, international prognostic index (IPI) ≤1, primary tumor diameter <7.5 cm, and patients who had complete response (CR) and received doxorubicin-contained chemotherapy (P<0.05). There was a trend toward superior outcome for patients who received combined therapy (surgery/chemotherapy/radiotherapy) (P=0.055). Patients who had CR, primary tumor diameter <7.5 cm and IPI score ≤1 were significantly associated with longer PFS at multivariate analysis. Conclusions: Primary testicular DLBCL had poorer survival. CR, primary tumor diameter and IPI were independent prognostic factors. The combined therapy of orchectomy, doxorubicin-contained chemotherapy and contralateral testicular radiotherapy (RT) seemed to improve survival.
    Chinese Journal of Cancer Research 08/2014; 26(4):459-65. DOI:10.3978/j.issn.1000-9604.2014.08.12 · 1.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Plm60-s is a pegylated liposomal mitoxantrone formulation, in which mitoxantrone was loaded into small unilamellar vesicles (~60 nm) made from solid lipid membrane. This two-arm, dose-escalating phase I study was designed to determine safety and pharmacokinetics of plm60-s, and to compare with those of conventional mitoxantrone injection (c-MI). Methods: Patients received an intravenous infusion of plm60-s at 6, 10, 12, 14, 16 and 18 mg/m(2) every 4 weeks. Three or 6 patients were in each group of dose level. If more than one third patients of a group experienced dose-limiting toxicity, dose climbing will stop. The control group of 3 patients received c-MI at 10 mg/m(2) every 28 days. Samples for pharmacokinetic studies were collected. The analysis of the safety and tolerability was done according to the record and laboratory examination, etc. Results: Twenty patients were enrolled. One grade 3 leukocytopenia occurred in plm60-s groups. Plm60-s was safer than c-MI at the same dose of 10 mg/m(2). Two complete responses and one partial response occurred in plm60-s group. In plasma, plm60-s exhibited sustained release of the content, resulting in the reduced peak concentrations and enhanced AUC of released MIT. Total mitoxantrone was linearly cleared, and mitoxantrone was predominantly in the liposomal encapsulation form. Repeated administration of plm60-s did not affect the clearance kinetics. Conclusions: At a dose of up to 18 mg/m(2), plm60-s could be well tolerated and potential efficacy could be observed. The pharmacokinetic profile of plm60-s was remarkably altered. Further investigations are in progression.
    Cancer Chemotherapy and Pharmacology 07/2014; 74(3). DOI:10.1007/s00280-014-2523-8 · 2.77 Impact Factor

  • Leukemia and Lymphoma 05/2014; 56(2):1-9. DOI:10.3109/10428194.2014.920504 · 2.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the efficacy and safety of gemcitabine combined with oxaliplatin (GEMOX) in lymphoma patients after failure of multiple chemotherapy regimens. The clinical data of 27 lymphoma patients, who received GEMOX regimen after failure of two or more prior chemotherapy regimens, were retrospectively reviewed. The predictive factors related to the clinical efficacy of GEMOX regimen were explored. The efficacy could be evaluated in 24 patients. Complete response was obtained in 4 patients (16.7%), partial response in 7 patients (29.1%), stable disease in 6 patients (25.0%), and progressive disease in 7 patients (29.1%), with an overall response rate of 45.8%. Among the eleven CR and PR patients, four patients were with diffuse large B cell lymphoma, four patients with Hodgkin's lymphoma, one with peripheral T cell lymphoma, one with mantle cell lymphoma and one with gastric mucosa-associated lymphoid tissue lymphoma. The median PFS time of the whole group was 8 months (95%CI, 1.6-14.4 months). For 11 CR and PR patients who had response to the GEMOX regimen, the median PFS time was 19 months (95%CI, 11.1-26.8 months). Major adverse response was hematologic toxicity. Among them, grade III or IV neutropenia appeared in 16 patients (59.3%), and grade III or IV thrombocytopenia appeared in 11 patients (40.7%). The sensitivity to the last chemotherapy was related to the efficacy of GEMOX regimen. The response rate was 83.3% in patients who had response to the last chemotherapy, and only 31.2% in the patients who failed to the last chemotherapy (P = 0.001). GEMOX regimen can get a better response rate in lymphoma patients after failure of multiple chemotherapy regimens, and with a good tolerance and acceptable safety. Some patients can get long-term survival. Patients sensitive to the last chemotherapy are more likely to benefit from GEMOX regimen.
    Zhonghua zhong liu za zhi [Chinese journal of oncology] 02/2014; 36(2):137-40.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Oral topotecan (Hycamtin(®)) has been recently approved for the treatment of relapsed small cell lung cancer (SCLC) in 2007, however, the bioavailability and pharmacokinetic data of topotecan for Chinese patients is still limited. Xinze(®) is a new and the only capsule formulation of topotecan used in China that is similar to Hycamtin(®). The current study aimed to investigate the absolute bioavailability and pharmacokinetics of Xinze(®) in Chinese patients with advanced cancers. On day 1, an IV dose of 1.5mg/m(2)/d as a 30min continuous infusion was administered. Patients took the oral topotecan at one of two dose levels: 1.5mg/m(2)/d (six patients) or 1.9mg/m(2)/d (seven patients) on day 2. Plasma pharmacokinetics of total topotecan and topotecan in the lactone form were performed on both days using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Single-nucleotide polymorphisms (SNPs) identified in exon 5 (421C>A) and in exon 2 (34G>A) in ATP-binding cassette sub-family G member 2 (ABCG2) were analyzed by direct sequencing. Safety assessments were performed throughout the study. The maximum plasma concentration (Cmax) reached at 1-2h and the elimination half-life time (T1/2) was approximately 4.2h after oral administration. The absolute bioavailability of total topotecan in the 1.5mg/m(2)/d and 1.9mg/m(2)/d groups averaged 41.23±11.8% and 36.00±14.8%, respectively. The patients with heterozygous SNPs had essentially the same bioavailability and pharmacokinetics. The bioavailability of topotecan after oral administration illustrates good systemic exposure at dosages of 1.5mg/m(2)/d and 1.9mg/m(2)/d over a five-day schedule in Chinese patients. On a dose-normalized basis, the values of Cmax and AUC0-t for total topotecan in Chinese patients were higher than in Caucasians following oral and intravenous administration, while the T1/2 was consistent.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 09/2013; 67(8). DOI:10.1016/j.biopha.2013.08.002 · 2.02 Impact Factor
  • Ning Li · Xiaohong Han · Jianliang Yang · Lin Gui · Yuanyuan Song · Ping Du · Yuankai Shi ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Xinze(®) is a new capsule formulation of topotecan being made in China which is similar to Hycamtin(®), the currently available oral formulation approved in 2007 for the treatment of relapsed small cell lung cancer (SCLC). As topotecan bioavailability and pharmacokinetic data for Chinese patients is limited, the aim of the study was to assess the absolute bioavailability and pharmacokinetics of Xinze(®) in Chinese patients with SCLC treated intravenously (i.v.) with 1.5mg/m(2)/d topotecan (Hycamtin(®)) on day 1 and treated orally with 1.5mg/m(2)/d topotecan on day 2. An ultra high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method was developed and validated for the determination of total topotecan (lactone and carboxylate forms) and of topotecan in the lactone form in human plasma samples. The method was validated with respect to selectivity, extraction recovery, matrix effect, linearity, intra- and inter-day precision, accuracy, and stability. The quantification limits were 0.5ng/mL for total topotecan and 0.1ng/mL for topotecan in the lactone form. The mean absolute bioavailability of total topotecan and topotecan in the lactone form was 42.24±12.9% and 47.18±16.9%, respectively, values which illustrate good systemic exposure. The presented results demonstrated this method can be a sensitive and efficient tool for bioavailability studies of topotecan.
    Journal of pharmaceutical and biomedical analysis 01/2013; 76C:252-256. DOI:10.1016/j.jpba.2012.12.033 · 2.98 Impact Factor
  • Wei Shi · Xiaohong Han · Jiarui Yao · Jianliang Yang · Yuankai Shi ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Interactions between histone deacetylases inhibitor suberoylanilide hydroxamic acid (SAHA) and anti-CD20 monoclonal antibody rituximab in mantle cell lymphoma have been examined both in vitro and in vivo. The combination of SAHA and rituximab synergistically induced apoptosis, concomitant with caspase activation and Bcl-2 downregulation. These events were associated with multiple perturbations in signal transduction pathways, including inactivation of cyto-protective nuclear factor (NF)-κB, Akt, extracellular signal-regulating kinase 1/2 (ERK1/2) and p38 mitogen-activated protein kinase (p38MAPK) pathways, and activation of c-jun N-terminal kinase (JNK) when pretreated with the pan-caspase inhibitor. Moreover, the combination of SAHA and rituximab significantly inhibited tumor growth in vivo and prolonged the survival of tumor-bearing mice. However, SAHA had no apparent effect on the CD20 expression in the two MCL cell lines. Taken together, our results demonstrate the synergistic anti-MCL activity of SAHA and rituximab, and build the framework for clinical trials using SAHA-rituximab combining regimen in the treatment of MCL.
    Leukemia research 04/2012; 36(6):749-55. DOI:10.1016/j.leukres.2012.01.027 · 2.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Factors affecting progenitor cell mobilization in patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) are incompletely understood. The aim of this retrospective study was to determine which factors are crucial for effective mobilization and collection of autologous peripheral blood stem cells (PBSC) prior to transplantation in Chinese patients. A total of 239 patients with lymphoma (198 NHL and 41 HL patients) underwent PBSC collection after mobilization with granulocyte-colony-stimulating factor (G-CSF) or G-CSF plus chemotherapy priming. Patient characteristics at diagnosis and transplant, including low Eastern Cooperative Oncology Group score (P = 0.013), lack of extranodal invasion (P = 0.034), previously administered radiotherapy regimens (P = 0.040), treatment with platinum prior to mobilization (P = 0.042), previous chemotherapy regimens (P = 0.001) and cycles (P < 0.001), and chemotherapy regimens (P < 0.001) were statistically significant for successful mobilization in multivariate analysis. Premobilization factors, including previous radiotherapy (P = 0.009), previous chemotherapy regimens (P = 0.043) and cycles (P = 0.039), low platelet count prior to mobilization (P = 0.042), and lower CD34+ cells in peripheral blood (PB) (P = 0.050) or bone marrow (BM) (P = 0.007) were considered possibly predictive of poor mobilization. We found the patients who had chemosensitive lymphoma had worse progress-free survival (PFS) than the patients with initial treatment and high risks (P = 0.017). Our analysis showed that high amounts of chemotherapy, radiotherapy, low platelet count, chemosensitive recurrent patients, combination chemotherapy plus G-CSF and low CD34+ cells in BM prior to mobilization could emerged as important predictive factors for mobilization failure in Chinese patients with NHL and HL.
    Journal of Clinical Apheresis 01/2012; 27(2):64-74. DOI:10.1002/jca.21204 · 1.79 Impact Factor
  • Yuankai Shi · Xiaohong Han · Xiaohui He · Jianliang Yang · Peng Liu ·
    [Show abstract] [Hide abstract]
    ABSTRACT: To observe the effect of cytosine arabinoside (Ara-C) combined with recombinant human granulocyte colony-stimulating factor (rhG-CSF) on mobilization of autologous peripheral blood stem cells (APBSCs) among malignant lymphoma patients and investigate appropriate dose of Ara-C. Twenty-two patients with malignant lymphoma were randomly divided into two groups: in group A 3 g/m2.d-1of Ara-C was administered by intravenous drip in 2 divided doses for two days with the total dose of 6 g/m(2); in group B 5 g/m(2).d(-1) of Ara-C was administered by intravenous drip in two divided doses for two days with the total dose of 10 g/m(2). Blood routine examination was made every day. rhG-SCF at the dose of 300 microg.body(-1).d(-1) was injected subcutaneously once a day since the next day when the white blood cells reached the nadir until the end of APBCS harvest. APBSC harvest began when WBC >/= 5.0 x 10(9)/L and finished when the accumulated mononuclear cells >/= 5 x 10(5)/kg. The median of days when nadir of WBC appeared was 7 days in group A and 10 days in group B. The median of absolute neutrophil count (ANC) at ite nadir was 0.9X109/L in group A and 0.2 x 10(9)/L in group B. The median of days when ANC reached its nadir was 9 days in group A and 13 days in group B. The median of dose of rhG-CSF was 4.35 microg.kg(-1).d(-1) in group A and 4.35 microg.kg(-1).d(-1) in group B. The median of day when rhG-SCF administration began was the 11th day in group A and the 12th day in group B. The median of rhG-SCF administration days was 5 days in group A and 6 days in group B. The median of day when APBSC harvest began was the 15th day after Ara-C administration in group A and the 16th day in group B. The median of harvest time was 2 days in both groups. The volume, speed, and time of each apheresis were similar in the two groups. The time consumed and number of APBSCs collected in each harvest and the total number of APBSCs collected were similar in these two groups. Ara-C combined with rhG-CSF is safe and highly effective for APBSC mobilization. 6 g/m(2) is the suitable dose for APBSC mobilization.
    Zhonghua yi xue za zhi 04/2002; 82(7):462-6.

Publication Stats

22 Citations
29.94 Total Impact Points


  • 2014-2015
    • Cancer Institute and Hospital, Chinese Academy of Medical Sciences
      Peping, Beijing, China
    • Peking Union Medical College Hospital
      Peping, Beijing, China
  • 2012
    • Chinese Academy of Medical Sciences
      Peping, Beijing, China
    • Chongqing Cancer Hospital and Institute
      Ch’ung-ch’ing-shih, Chongqing Shi, China